Article Information
History
- February 18, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Claire Donnicia,*,#,
- Natasha Ilincicb,*,
- Christian Caoa,
- Caseng Zhangc,
- Gabriel Deveauxa,
- David A. Cliftond,
- David Buckeridgee,
- Niklas Bobrovitza,d and
- Rahul K. Aroraa,d
- aCumming School of Medicine, University of Calgary, Calgary, AB, Canada, 3330 Hospital Dr NW, Calgary, AB T2N 4N1
- bTemerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada, 27 King’s College Cir, Toronto, ON M5S 1A1
- cFaculty of Health Sciences, McMaster University, Hamilton, ON, Canada, 1280 Main St W, Hamilton, ON L8S 4L8
- dInstitute of Biomedical Engineering, University of Oxford, UK, Old Road Campus Research Building, Headington, Oxford OX3 7DQ
- eFaculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada, 3605 Rue de la Montagne, Montreal, QC H3G 2M1
- ↵#Corresponding author:
Claire Donnici, MD/MSc Student, University of Calgary, Calgary, AB, Canada, SeroTracker Research Team, claire.donnici{at}ucalgary.ca, phone: 1-403-561-0619
Posted February 18, 2022.
Timeliness of reporting of SARS-CoV-2 seroprevalence results and their utility for infectious disease surveillance
